{"title":"Epidemiological and clinical characteristics of patients in the alveolar echinococcosis registry, France, 1982 to 2021.","authors":"Jenny Knapp, Florent Demonmerot, Houssein Gbaguidi-Haore, Carine Richou, Dominique Angèle Vuitton, Anne-Pauline Bellanger, Solange Bresson-Hadni, Laurence Millon","doi":"10.2807/1560-7917.ES.2025.30.32.2500041","DOIUrl":null,"url":null,"abstract":"<p><p>BACKGROUND<i>Echinococcus multilocularis</i> is a parasite causing alveolar echinococcosis (AE), a severe disease affecting primarily the liver. Surveillance of this non-notifiable disease in France is performed by the National Reference Center for Echinococcoses (NRC-E).AIMWe aimed to analyse changes in epidemiological, clinical and survival data of patients with AE over time.METHODSWe described and analysed data from 906 AE patients reported to the NRC-E over three periods: 1982-1999, 2000-2010 and 2011-2021, using regression methods and survival analysis methods.RESULTSAt diagnosis, the median age of the patients was 60.0 years, most (770; 85.0%) resided in an endemic region and 483 (53.3%) in a rural area. The percentage of asymptomatic patients increased significantly from 19.1% (48/251) in 1982-1999 to 56.2% (209/372) in 2011-2021 (p < 0.001). The number of patients with weakened immune systems increased significantly in 2000-2021 (p < 0.001). Most (761/836; 91.0%) patients were treated with antiparasitic drugs and 402 (44.4%) underwent surgery. The number of surgical interventions decreased significantly during the study period (p = 0.007). Palliative surgery decreased, curative hepatic resection became more commonly performed (p < 0.001). Multivariate analysis showed a lower risk of death in the first 10-year follow-up in patients diagnosed after 2000 and those receiving benzimidazoles (sub-distribution hazard ratio (SHR) = 0.43; 95% confidence interval (CI): 0.28-0.66; p < 0.001).CONCLUSIONInternational recommendations for treating all patients with benzimidazoles and favouring curative hepatic resection, whenever possible, were generally followed and associated with better survival. We recommend national and European-wide registries to ensure effective surveillance of AE.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 32","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355909/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2025.30.32.2500041","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUNDEchinococcus multilocularis is a parasite causing alveolar echinococcosis (AE), a severe disease affecting primarily the liver. Surveillance of this non-notifiable disease in France is performed by the National Reference Center for Echinococcoses (NRC-E).AIMWe aimed to analyse changes in epidemiological, clinical and survival data of patients with AE over time.METHODSWe described and analysed data from 906 AE patients reported to the NRC-E over three periods: 1982-1999, 2000-2010 and 2011-2021, using regression methods and survival analysis methods.RESULTSAt diagnosis, the median age of the patients was 60.0 years, most (770; 85.0%) resided in an endemic region and 483 (53.3%) in a rural area. The percentage of asymptomatic patients increased significantly from 19.1% (48/251) in 1982-1999 to 56.2% (209/372) in 2011-2021 (p < 0.001). The number of patients with weakened immune systems increased significantly in 2000-2021 (p < 0.001). Most (761/836; 91.0%) patients were treated with antiparasitic drugs and 402 (44.4%) underwent surgery. The number of surgical interventions decreased significantly during the study period (p = 0.007). Palliative surgery decreased, curative hepatic resection became more commonly performed (p < 0.001). Multivariate analysis showed a lower risk of death in the first 10-year follow-up in patients diagnosed after 2000 and those receiving benzimidazoles (sub-distribution hazard ratio (SHR) = 0.43; 95% confidence interval (CI): 0.28-0.66; p < 0.001).CONCLUSIONInternational recommendations for treating all patients with benzimidazoles and favouring curative hepatic resection, whenever possible, were generally followed and associated with better survival. We recommend national and European-wide registries to ensure effective surveillance of AE.
期刊介绍:
Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.